人类应用的基因治疗用嵌合抗原受体重新编程的特异性T细胞

i****b

The human application of genetherapy to re-program T-cell specificity using chimeric antigen receptors

人类应用的基因治疗用嵌合抗原受体重新编程的特异性T细胞

Abstract

      Theadoptive transfer of T cells is a promising approach to treat cancers. Primaryhuman T cells can be modified using viral and non-viral vectors to promote thespecific targeting of cancer cells via the introduction of exogenous T-cellreceptors (TCRs) or chimeric antigen receptors (CARs). This gene transferdisplays the potential to increase the specificity and potency of theanticancer response while decreasing the systemic adverse effects that arisefrom conventional treatments that target both cancerous and healthy cells. Thisreview highlights the generation of clinical-grade T cells expressing CARsfor  immunotherapy, the use of thesecells to target B-cell malignancies and, particularly, the first clinicaltrials deploying the Sleeping Beauty gene transfer system, which engineers Tcells to target CD19+ leukemia and non-Hodgkin’s lymphoma.

摘要:

   T细胞的肿瘤免疫过继治疗是一个有希望治疗癌症的方法。

通过病毒或非病毒载体将外源T细胞受体（TCR）或嵌合抗原受体（CARs）引入人原代T细胞，可获得特异性识别肿瘤的能力

，并降低对正常细胞的不良作用。本综述突出表达用于免疫治疗的CAR-T的生产，利用这些细胞的治疗B-细胞恶性肿瘤，特别有效利用“Sleeping Beauty gene”转移系统，该系统工程的T细胞为靶向CD19治疗白血病和非何杰金氏淋巴瘤的第一个临床试验。

鬼*寒

发帖者 能把全文翻译完不？